These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991 [TBL] [Abstract][Full Text] [Related]
15. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA; Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964 [TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Sohn HS; Kwon JW; Shin S; Kim HS; Kim H J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867 [TBL] [Abstract][Full Text] [Related]
17. Role of tyrosine kinase inhibitors in lung cancer. Ansari J; Palmer DH; Rea DW; Hussain SA Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298 [TBL] [Abstract][Full Text] [Related]
18. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. Dancey JE Cancer Cell; 2004 May; 5(5):411-5. PubMed ID: 15144948 [TBL] [Abstract][Full Text] [Related]
19. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials. Qi WX; Fu S; Zhang Q; Guo XM Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826 [TBL] [Abstract][Full Text] [Related]
20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]